Long-term survival of a patient with small-cell lung cancer (SCLC) following treatment with thalidomide and combination chemotherapy.
Thalidomide, an angiogenesis inhibitor is currently used in clinical trials in the US and Europe in combination with chemotherapy for the treatment of various solid tumors. The prognosis of patients suffering from small-cell lung cancer (SCLC) is poor. A 73-year-old female with extensive disease of SCLC was given six courses of chemotherapy with adriamycine, cyclophasphamide and oncovine, which led to complete remission of the disease. Following written informed consent, the patient has been treated with thalidomide 200 mg orally on a daily basis for 2 years and 5 months. There has been no sign of tumor recurrence during the follow-up. This case underlines the possible role of additional treatment with angiogenesis inhibitors in combination with traditional chemotherapy in the therapy of SCLC. Although there is no proof that thalidomide contributed to this good outcome and no conclusions can be drawn from this treatment in a single patient, further studies may determine the role of thalidomide as an adjuvant antiangiogenic agent in the therapy of SCLC.
Mall
J W
JW
Department of General, Visceral, Vascular and Thoracic Surgery, University Hospital Charité of the Humboldt University, Berlin, Germany. julianmall@hotmail.com
Philipp
A W
AW
Mall
W
W
Pollmann
C
C
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D018288:Carcinoma, Small Cell / Q000188:drug therapy / Q000401:mortality* / Q000556:secondary; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis / Q000188:drug therapy*; D017741:Survivors; D013792:Thalidomide / Q000494:pharmacology*
D020533:Angiogenesis Inhibitors; D013792:Thalidomide